Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Metabolic SyndromeNonalcoholic Fatty Liver Disease
Interventions
DRUG

Sodium Octanoate Breath Test

100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.

Trial Locations (2)

23298

Virginia Commonwealth University, Richmond

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Meridian Bioscience, Inc.

INDUSTRY

lead

Virginia Commonwealth University

OTHER